Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Breast Cancer Research and Treatment
|
November 10, 2000
Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability
A Venturino, D Comandini, C Granetto, et al.
Journal of the American Geriatrics Society
|
March 25, 2000
A loading dose of tamoxifen followed by a standard dose in frail older women with breast cancer is feasible and effective
L Repetto, A Venturino, D Comandini, et al.
Cancer
|
February 26, 1998
Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions
L Repetto, A Venturino, M Vercelli, et al.
Anticancer Research
|
April 27, 1999
Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells
L Repetto, M O Vannozzi, E Balleari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2009
The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer
G Numico, M Anfossi, G Bertelli, et al.
Oncology
|
March 1, 1997
Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study
L Miglietta, D Amoroso, M Bruzzone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
C Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Breast Cancer Research and Treatment
|
November 10, 2000
Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability
A Venturino, D Comandini, C Granetto, et al.
Journal of the American Geriatrics Society
|
March 25, 2000
A loading dose of tamoxifen followed by a standard dose in frail older women with breast cancer is feasible and effective
L Repetto, A Venturino, D Comandini, et al.
Cancer
|
February 26, 1998
Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions
L Repetto, A Venturino, M Vercelli, et al.
Anticancer Research
|
April 27, 1999
Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells
L Repetto, M O Vannozzi, E Balleari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2009
The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer
G Numico, M Anfossi, G Bertelli, et al.
Oncology
|
March 1, 1997
Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study
L Miglietta, D Amoroso, M Bruzzone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
C Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
Page
of 2